Speaker Profile
Biography
Most recently served as Senior Vice President and Global Head for Personalized Healthcare, Product Development at GenentechRoche. Prior to joining Genentech, Mark was a member of the founding leadership team and Head of Clinical Development and Medical Affairs at GRAIL, where his team built one of the largest clinical research programs in genomic medicine aimed at early cancer detection. Some of his previous roles include Lead for Oncology Clinical Sciences at Googlex Life Sciences, Chief Medical Officer at Boreal Genomics, and Vice President of Oncology Development at Genomic Health, where he led the successful development and validation of the Oncotype DX Colon and Prostate Cancer Assays.
Talk
Generation and Application of Prospective External Control Arms (ProECA)
Reducing reliance on traditional randomized trials is critical to accelerating and de-risking drug development. Broad adoption of external controls requires prospectively generated fit-for-purpose data aligned to trial designs, including trial compatible end points and prognostic covariates. N-Powers ProECA platform is already in use in early development, with future late-stage applications.
Large-Scale Data Solutions Showcase:
N-Power Medicine
N-Power Medicine is transforming drug development by embedding prospective, trial-grade research into routine oncology care.
Its network and infrastructure enable scalable Prospective External Control Arms and novel trial designs across community settings.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Large Scale Data Solutions Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.




